Abstract
The absorption of L-thyroxine (L-T4) is influenced by several factors, such as patient’s age, drugs interference, absorption kinetics, dietary habits, adherence to therapy. Issues in the L-T4 absorption could be encountered by patients affected by celiac disease, because of drug malabsorption. We enrolled 22 patients with celiac disease and high serum thyrotropin (TSH) levels in treatment with L-T4 in tablet formulation. All subjects switched to a L-T4 liquid formulation, with no change in the dosage. A circulating TSH levels normalisation/reduction has been obtained in all the patients after the switch from L-T4 in tablet formulation to an oral liquid one with the same L-T4 dosage. Nine subjects switched back again to receive L-T4 in tablets (at the same dosage) reporting a worsening of TSH levels, and TSH values fell into the hypothyroid range. In conclusion, malabsorption issues could be overcome through oral L-T4 liquid formulation administration, in this way leading to ameliorate the management of patients affected by celiac disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
